Francesco Maria Rossi

Dr. Francesco Maria Rossi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
KAKatie S. Allen
Katie S. Allen
QLQian Luo
Qian Luo
JWJeff Whittle
Jeff Whittle
BBBernard S. Black
Bernard S. Black
Objective: This study aimed to assess COVID-19 vaccine effectiveness against death (VE), controlling for healthy vaccinee bias. Methods: We link all adult deaths through year-end 2022 in the State of Indiana, U.S.A., to vaccination records and identify which deceased received primary vaccination (measured as either one or two initial doses) and which received one or two booster doses. We measure COVID-19 mortality with the COVID Excess Mortality Percentage (CEMP). CEMP is calculated, for a group defined by various characteristics (age, sex, time period), as COVID-19 deaths divided by non-COVID natural deaths. The CEMP outcome measure accounts for healthy vaccinee bias by using non-COVID natural mortality to control for differences in population health. Results: We find a large healthy vaccinee bias. Controlling for this bias, we find substantial VE for primary vaccination and the first booster dose during the first five vaccine-available calendar quarters, from 1Q2021 through 1Q2022 (end of Omicron infection wave). However, over 2Q–4Q2022, we find no evidence for primary-vaccination VE, and find moderate but statistically insignificant booster VE, which largely wanes by 4Q2022. Conclusions: It is known that by 2Q2022, most people had natural immunity from prior COVID-19 infection. Thus, our results for 2Q–4Q2022 largely reflect comparing hybrid (infection plus vaccination) immunity to infection-only immunity. In this period, we find negligible mortality benefit from primary vaccination, and moderate but waning benefit from a booster dose. Policy Implications: Controlling for healthy vaccinee bias is crucial when estimating VE. We found limited VE against COVID-19 mortality over 2Q–4Q2022, but lacked data for more recent periods.

25 March 2026 in Journal of Law & Empirical Analysis
Verified
Journal Article
Open access
BBBernard S. Black
Bernard S. Black
FRFrancesco Maria Rossi
Francesco Maria Rossi
JTJeffrey Traczynski
Jeffrey Traczynski
VUVictoria Udalova
Victoria Udalova
We use staggered difference-in-differences and panel data methods to study the factors that predict medical malpractice (“med mal”) insurance premia, using national data on three specialties (internal medicine, general surgery, ob-gyn) from Medical Liability Monitor over 1992 to 2017. A difference-in-differences analysis of states that adopted caps during our sample period provides evidence supporting a causal link between cap adoption and higher premia, lower direct costs (payouts plus defense costs), and thus much higher profitability (proxied by the premium-to-direct-cost ratio). The savings to insurers from lower direct costs, following damage cap adoption, are at most partially reflected in premia even over long time periods. Instead, insurers in new-cap states have been able to charge apparently supra-competitive prices for a sustained period. In the panel data analysis, we estimate long run elasticities of premia to direct cost, allowing for lags of up to four years, of only around +0.40, when one might expect elasticities near one. Also, the premium-to-cost ratio, which one might expect in competitive markets to be fairly constant over time, varies widely both across states at a given time and within states across time.

25 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
QLQian Luo
Qian Luo
JWJeff Whittle
Jeff Whittle
KMKevin McGUrk
Kevin McGUrk
BBBernard S. Black
Bernard S. Black
This Supplementary Material provides additional results and methods details for Farzana et al. (2026), Pfizer versus Moderna COVID-19 Vaccine Effectiveness against Mortality: Evidence from Linked Mortality and Vaccination Records in Indiana.

13 July 2026 in American Journal of Epidemiology
Verified
Journal Article
Closed access
FRFrancesco Maria Rossi
Francesco Maria Rossi
LFLorenzo Franchi
Lorenzo Franchi
VAVladimir Atanasov
Vladimir Atanasov
NBNatalia Barreto
Natalia Barreto
JWJeff Whittle
Jeff Whittle
BBBernard S. Black
Bernard S. Black
We study life expectancy loss (LEL) from the COVID-19 pandemic in the United States from March 2020 through April 2023. We use individual-level death-certificate data and the cohort-based approach to life expectancy. We also examine how LEL varies with age, gender, race/ethnicity, and county-level socioeconomic status (county-SES). The United States recorded 983 000 COVID-19 deaths. The COVID-19 mortality rate (the fraction of the population who died of COVID-19) was 0.30%. An upper bound estimate of years of life lost per person (YLL) is 14.6 years (thus population loss of 14.32 million life-years). Estimated LEL based on this YLL estimate is 0.043 years (16 days). However, LEL rose rapidly with age averaging 8 weeks for ages 75+. LEL was substantially higher for Native Americans, Blacks, and Hispanics than for Whites at all ages, but lower for Asians. LEL also increased as county-SES decreased. Our cohort-based LEL estimates are a small fraction of period-based estimates during the pandemic, which were based on mortality in a particular year and assumed the pandemic would continue indefinitely with no change in severity. Using current life expectancies, cohort-based LEL for the COVID-19 pandemic was a fraction of LEL for the 1918 influenza pandemic (14 weeks), but well above 3 recent, severe influenza seasons (average of 0.12 weeks).

21 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
BBBernard S. Black
Bernard S. Black
CBCourtney K. Blackwell
Courtney K. Blackwell
EKEmily Knapp
Emily Knapp
GFGarrett Fuselier
Garrett Fuselier
FRFrancesco Maria Rossi
Francesco Maria Rossi
This is a pre-analysis plan for a project using data from the Environmental Influences on Child Health Outcomes Program (ECHO). The project will develop an individual socio-economic status (SES) index, use this index to predict child health outcomes, assess the correlation between the individual-SES index and its elements with an area-level SES index, the Social Deprivation Index (SDI) and include both the individual-SES and area SES indices as separate predictors of child health outcomes in the same regression. This pre-analysis plan provides details on sample selection, construction of the individual-SES index, and correlation between individual and area-level SES measures. It was prepared without using outcome data, other than to select outcomes for future analysis and assess the sample size available for each outcome.

20 August 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
SFSadia Farzana
Sadia Farzana
FRFrancesco Maria Rossi
Francesco Maria Rossi
QLQian Eric Luo
Qian Eric Luo
JWJeff Whittle
Jeff Whittle
KMKevin McGurk
Kevin McGurk
BBBernard S. Black
Bernard S. Black
Objective: It is commonly believed in the public health community that the mRNA vaccines from Pfizer and Moderna were broadly similar in preventing COVID-19 mortality, with perhaps a small advantage for Moderna. We revisit this question, using a research design that controls for healthy-vaccinee bias. Methods: We studied deaths among persons aged 15 years or greater from January 2021 through December 2022 in Indiana, linked to vaccination records, using an outcome measure, namely COVID-19 Excess Mortality Percentage (CEMP), which uses non-COVID natural mortality to control for HVB. Results: We find both large healthy-vaccinee bias for both vaccines, and larger bias for Pfizervaccinees: Pfizer recipients were healthier and thus would have faced lower COVID-19 mortality without vaccination. For ages 60+, we find almost 50% higher COVID-19 remaining mortality risk (RMR) for Pfizer vaccinees receiving primary vaccination over a “core period” from 2Q2021 through 1Q2022: the average Pfizer/Moderna RMR ratio was 1.49. For ages 15–59, this ratio was 1.25, but was not statistically significant. For booster dose for ages 60+, the average Pfizer/Moderna RMR ratio was 1.34. For 2Q2022 through 4Q2022, after the major Omicron wave, we find much lower vaccine effectiveness and no significant Pfizer–Moderna difference. Conclusions: During the period with both good vaccine availability and high COVID-19 mortality (2Q-2021–1Q2022), the Moderna vaccine was associated with lower COVID-19 mortality, relative to the Pfizer vaccine. A possible explanation is the higher Moderna dose (100 μg vs. 30 for Pfizer). After that period, a high percentage of the population had natural immunity from prior COVID-19 infection; we find only small mortality gains from vaccination, with no significant Pfizer–Moderna difference. Policy Implications: Controlling for healthy-vaccinee bias, Moderna was associated with lower COVID-19 mortality, relative to Pfizer. This difference was not known in real-time due to the failure of the available studies to address healthy-vaccinee bias. Controlling for such bias is vital when making vaccination policy.